200 million US dollars big cooperation! Develop immune tumor antibody products
April 03, 2018 Source: WuXi PharmaTech
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Today, Compugen announced an exclusive licensing agreement with AstraZeneca's global biologics research and development subsidiary, MedImmune, to promote the development of bispecific and multispecific immune tumor antibody products.
Compugen is a company that uses its widely available predictive discovery infrastructure to identify new drug targets and develop "first-in-class" therapies in the field of cancer immunotherapy. The company's research and development pipeline is based on its discovery of new drug targets, mainly immunological checkpoint drug candidates, including T-cell immune checkpoints and myeloid target projects.
Antibodies are naturally occurring components of the immune system and can specifically bind to a target protein through two identical arms. A bispecific antibody refers to the exchange of one arm of an antibody with another arm of an antibody having a different target specificity by genetic engineering to enable binding of different proteins. Multispecific antibodies refer to genetic engineering to modify an antibody to bind three or more target proteins. These engineered antibodies can initiate a variety of mechanisms to treat disease in a single molecule and can therefore be developed into therapeutic agents.
Under the terms of the agreement, Compugen will provide MedImmune with an exclusive license to develop bispecific and multispecific antibody products derived from the Compugen pipeline project. MedImmune has the right to create multiple products under this license and will be solely responsible for all R&D and promotion activities. Compugen will receive a $10 million advance payment and is eligible for development, regulatory and promotional milestone payments for the first product of up to $200 million, as well as royalties for future product sales. If more products are developed, Compugen will receive additional milestone payments and royalties. Compugen will retain all other rights to its entire project pipeline, including as a monotherapy and in combination with other products.
â–²Compugen research and development pipeline (Source: Compugen official website)
“We are pleased to announce an agreement with MedImmune, a global leader in the development of antibody oncology,†said Dr. Anat Cohen-Dayag, President and CEO of Compugen. “This license allows us to take specific science in the project. Progress is being promoted while continuing to advance our main projects to clinical trials. We are committed to implementing our strategy and selectively collaborating with biopharmaceutical companies to develop 'first-in-class' products to target our diversity , computer-derived target combinations."
"This agreement with Compugen will support our ability to develop new immunotherapeutic targets, and MedImmune's expertise in antibody engineering can advance our therapeutic goals by providing cancer patients with treatments to improve their Life," said Dr. Ronald Herbst, vice president of cancer research at MedImmune.
We look forward to the cooperation between the two companies to produce meaningful immune tumor antibody products, bringing new hope for cancer patients.
Reference materials:
[1] Compugen Announces Exclusive License Agreement With MedImmune for the Development of Bi-Specific and Multi-Specific Antibody Products
[2] Compugen official website
Foot Spa Massager,Bath Foot Massager Machine,Foot Spa Bath,Bath Foot Massager With Bubble
Huaian Mimir Electric Appliance Co., LTD , https://www.footspamachine.com